Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

The Senate is poised to vote this week on President Donald Trump's rescissions package requesting roughly $9.4 billion in ...

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

Global deaths from AIDS have dropped to their lowest levels in more than 30 years, but US funding cuts could soon reverse that progress.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir. Research shows the shot could help end Aids in ...

The U.S. Senate will begin voting as soon as Tuesday on President Donald Trump's request to slash $9.4 billion in spending on ...

This 2011 electron microscope image made available by the Centers for Disease Control shows HIV virions. On Wednesday, Sept.

The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...